[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612073":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":33,"locations":42,"responsibleParty":89,"collaborators":38,"id":91,"slug":38,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":38,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":38,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":38,"overallStatus":45,"whyStopped":38,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","Mild Hepatic Impairment",[13],"Drug: BMS-986435",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm B","Moderate Hepatic Impairment",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arm C","Matched participants with normal hepatic function",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","BMS-986435","Specified dose on specified days",[9,15,19],[29],"MYK-224",[31],{"name":5,"affiliation":5,"role":32},"STUDY_DIRECTOR",[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286",null,"Clinical.Trials@bms.com",{"name":41,"role":36,"phone":38,"phoneExt":38,"email":38},"First line of the email MUST contain the NCT# and Site #.",[43,61,75],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Arizona Clinical Trials","RECRUITING","Chandler","Arizona","85225","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-111.84125,33.30616,{"lat":55,"lon":54},[58],{"name":59,"role":36,"phone":60,"phoneExt":38,"email":38},"Anita Kohli, Site 0003","434-825-0921",{"facility":62,"status":45,"city":63,"state":64,"zip":65,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Panax Clinical Research","Miami Lakes","Florida","33014",{"type":52,"coordinates":67},[68,69],-80.30866,25.90871,{"lat":69,"lon":68},[72],{"name":73,"role":36,"phone":74,"phoneExt":38,"email":38},"Robert Perry, Site 0002","305-698-4500",{"facility":76,"status":45,"city":77,"state":78,"zip":79,"country":49,"countryCode":50,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Texas Liver Institute","San Antonio","Texas","78215",{"type":52,"coordinates":81},[82,83],-98.49363,29.42412,{"lat":83,"lon":82},[86],{"name":87,"role":36,"phone":88,"phoneExt":38,"email":38},"Eric Lawitz, Site 0001","210-253-3426",{"type":90,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100612073",false,"NCT07248839","A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment","A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Mild and Moderate Hepatic Impairment","Inclusion Criteria:\n\n* Participant must have documented LVEF ≥ 60% (2D biplane Simpson's Method) and absence of cardiac abnormality.\n* Participant must have body weight of \\> 50 kg and BMI of 18.0 kg\u002Fm2 through 40 kg\u002Fm2, inclusive, at screening.\n* Participants must have adequate renal function at screening as evidenced by an eGFR \\> 60 mL\u002Fmin\u002F1.73 m2 for participants calculated with the CKD-EPI Creatinine Equation (2021).\n\nExclusion Criteria:\n\n* Participants must not have history of or current uncontrolled or unstable clinically significant disorder, condition, or disease that, in the opinion of the investigator and CRO MM, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.\n* Participants must not have head injury in the last 2 years, intracranial tumor, or aneurysm.\n* Participants must not have history of malignancy of any type, except in situ cervical cancer \\>5 years prior to the screening visit or surgically excised non-melanomatous skin cancer \\>2 years prior to the screening visit.\n* Participants must not have History of heart disease (including coronary artery disease, heart failure\u002FLV systolic dysfunction, cardiomyopathy, or clinically significant structural disease).\n* Other protocol defined inclusion\u002Fexclusion criteria applies.",true,"ALL","18 Years","75 Years",{"count":102,"type":103},24,"ESTIMATED","INTERVENTIONAL",[106],"PHASE1","The purpose of this study is to determine the pharmacokinetic and safety of BMS-986435 in participants with normal hepatic function and participants with different degrees of hepatic impairment",[109,110],"Healthy Volunteers","Hepatic Impairment","2026-06-10",{"date":113,"type":114},"2026-06-12","ACTUAL",{"date":116,"type":114},"2025-12-15",{"date":118,"type":103},"2026-08-05",{"name":5,"class":6},3]